SCHEMBL622565

SCHEMBL622565

CC(C)COc1cc(N2CCN(C(=O)c3c4ccccc4nn3C)CC2)ncn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 2/20 0.43
PDE2A O00408 1/20 0.41
HTR3E A5X5Y0 1/20 0.38
HTR3B O95264 1/20 0.38
HTR3A P46098 1/20 0.38
HTR3D Q70Z44 1/20 0.38
HTR3C Q8WXA8 1/20 0.38
HSD17B10 Q99714 4/20 0.37
ALOX15 P16050 1/20 0.37
KDM4E B2RXH2 4/20 0.36
MAPK1 P28482 5/20 0.36
TP53 P04637 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 3/20 0.36
MAPT P10636 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL623694 0.86 RAB9A (0.42) MGLLPDE2AHSD17B10KDM4EMAPK1
SCHEMBL622626 0.83 DRD2 (0.52) MGLLPDE2AHSD17B10ALOX15KDM4E
SCHEMBL624230 0.83 PDE2A (0.46) MGLLPDE2AHSD17B10ALOX15KDM4E
SCHEMBL623195 0.81 MGLL (0.41) MGLLHTR3EHTR3BHTR3AHTR3D
SCHEMBL624515 0.80 GRM5 (0.42) MGLLHSD17B10ALOX15KDM4EMAPK1
SCHEMBL623777 0.80 P2RY12 (0.46) MGLLHSD17B10ALOX15KDM4EMAPK1
SCHEMBL624477 0.80 MEN1 (0.45) MGLLHTR3EHTR3BHTR3AHTR3D
SCHEMBL624033 0.80 MAPT (0.40) TP53ALDH1A1HPGDMAPTMEN1
SCHEMBL623189 0.79 PTK2 (0.51) MGLLPDE2AMEN1POLBKMT2A
SCHEMBL624496 0.79 TSHR (0.53) MGLLKDM4EMAPK1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G MGLL 3566/4885PDE2A 475/4885HTR3E 2984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.